Detection of cannabinoid agonist evoked increase in BOLD contrast in rats using functional magnetic resonance imaging

Adams, 1996, Cannabis: pharmacology and toxicology in animals and humans, Addiction, 91, 1585, 10.1111/j.1360-0443.1996.tb02264.x Bloom, 1997, Cannabinoid-induced alterations in regional cerebral blood flow in the rat, Pharmacol. Biochem. Behav., 57, 625, 10.1016/S0091-3057(96)00475-3 Buxton, 1997, A model for the coupling between cerebral blood flow and oxygen metabolism during neural stimulation, J. Cereb. Blood. Flow Metab., 17, 64, 10.1097/00004647-199701000-00009 Cheer, 2000, Cannabinoid receptors and reward in the rat: a conditioned place preference study, Psychopharmacology (Berl.), 151, 25, 10.1007/s002130000481 Cheer, 2003, Differential cannabinoid-induced electrophysiological effects in rat ventral tegmentum, Neuropharmacology, 44, 633, 10.1016/S0028-3908(03)00029-7 Chen, 1993, Ventral tegmental microinjection of delta 9-tetrahydrocannabinol enhances ventral tegmental somatodendritic dopamine levels but not forebrain dopamine levels: evidence for local neural action by marijuana’s psychoactive ingredient, Brain Res., 621, 65, 10.1016/0006-8993(93)90298-2 Chen, 1997, Detection of dopaminergic neurotransmitter activity using pharmacologic MRI: correlation with PET, microdialysis, and behavioral data, Magn. Reson. Med., 38, 389, 10.1002/mrm.1910380306 Compton, 1996, In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity, J. Pharmacol. Exp. Ther., 277, 586 Dewey, 1986, Cannabinoid pharmacology, Pharmacol Rev., 38, 151 Diana, 1998, Increase in meso-prefrontal dopaminergic activity after stimulation of CB1 receptors by cannabinoids, Eur. J. Neurosci., 10, 2825, 10.1111/j.1460-9568.1998.00292.x Fields, 2000, Pain modulation: expectation, opioid analgesia and virtual pain, Prog. Brain Res., 122, 245, 10.1016/S0079-6123(08)62143-3 Floyd, 2000, Orbitomedial prefrontal cortical projections to distinct longitudinal columns of the periaqueductal gray in the rat, J. Comp. Neurol., 422, 556, 10.1002/1096-9861(20000710)422:4<556::AID-CNE6>3.0.CO;2-U Freedland, 2002, Dose-dependent effects of Delta9-tetrahydrocannabinol on rates of local cerebral glucose utilization in rat, Synapse, 45, 134, 10.1002/syn.10089 French, 1997, Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra, Neuroreport., 8, 649, 10.1097/00001756-199702100-00014 French, 1997, delta9-Tetrahydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opioid receptors, Neurosci. Lett., 226, 159, 10.1016/S0304-3940(97)00278-4 Friston, 1995, Human brain mapping 1:214-220 [SPM_3] statistical parametric maps in functional imaging: A general linear approach, Human Brain Mapping, 2, 189, 10.1002/hbm.460020402 Gardner, 1991, Marijuana’s interaction with brain reward systems: update 1991, Pharmacol. Biochem. Behav., 40, 571, 10.1016/0091-3057(91)90365-9 Gatley, 1998, Imaging the brain marijuana receptor: development of a radioligand that binds to cannabinoid CB1 receptors in vivo, J. Neurochem., 70, 417, 10.1046/j.1471-4159.1998.70010417.x Griffin, 1999, Evaluation of the cannabinoid CB2 receptor-selective antagonist, SR144528: Further evidence for cannabinoid CB2 receptor absence in the rat central nervous system, Eur. J. Pharmacol. Jul 14, 377, 117, 10.1016/S0014-2999(99)00402-1 Haller, 2002, The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety, Eur. J. Neurosci., 16, 1395, 10.1046/j.1460-9568.2002.02192.x Hennig, 1986, RARE imaging: a fast imaging method for clinical MR, Magn. Reson. Med., 3, 823, 10.1002/mrm.1910030602 Lake, 1997, Cannabinoid-induced hypotension and bradycardia in rats mediated by CB1-like cannabinoid receptors, J. Pharmacol. Exp. Ther., 281, 1030 Lichtman, 1997, The selective cannabinoid antagonist SR 141716A blocks cannabinoid-induced antinociception in rats, Pharmacol. Biochem. Behav., 57, 7, 10.1016/S0091-3057(96)00121-9 Lichtman, 1995, Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats, Psychopharmacology (Berl.), 119, 282, 10.1007/BF02246292 Maldonado, 2002, Study of cannabinoid dependence in animals, Pharmacol. Ther. Aug 95, 153, 10.1016/S0163-7258(02)00254-1 Marota, 2000, Cocaine activation discriminates dopaminergic projections by temporal response: an fMRI study in rat, Neuroimage., 11, 13, 10.1006/nimg.1999.0520 Martin, 1995, An examination of the central sites of action of cannabinoid-induced antinociception in the rat, Life Sci., 56, 2103, 10.1016/0024-3205(95)00195-C Martin, 1996, Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: correlation between electrophysiological and antinociceptive effects, J. Neurosci., 16, 6601, 10.1523/JNEUROSCI.16-20-06601.1996 Martin, 1998, Cannabinoid receptor-mediated inhibition of the rat tail-flick reflex after microinjection into the rostral ventromedial medulla, Neurosci. Lett., 242, 33, 10.1016/S0304-3940(98)00044-5 Martin, 1999, Anatomical basis for cannabinoid-induced antinociception as revealed by intracerebral microinjections, Brain Res., 822, 237, 10.1016/S0006-8993(98)01368-7 Ogawa, 1992, Intrinsic signal changes accompanying sensory stimulation: functional brain mapping with magnetic resonance imaging, Proc. Natl. Acad. Sci. USA, 89, 5951, 10.1073/pnas.89.13.5951 Ovadia, 1995, Characterization of the hypothermic effect of the synthetic cannabinoid HU210 in the rat. Relation to the adrenergic system and endogenous pyrogens, Neuropharmacology, 34, 175, 10.1016/0028-3908(94)00133-D Palazzo, 2001, Metabotropic and NMDA glutamate receptors participate in the cannabinoid-induced antinociception, Neuropharmacology, 40, 319, 10.1016/S0028-3908(00)00160-X Pontieri, 1999, Metabolic mapping of the effects of WIN 55212-2 intravenous administration in the rat, Neuropsychopharmacology, 21, 773, 10.1016/S0893-133X(99)00064-0 Rinaldi-Carmona, 1994, SR141716A, a potent and selective antagonist of the brain cannabinoid receptor, FEBS Lett., 350, 240, 10.1016/0014-5793(94)00773-X Sokoloff, 1977, Relation between physiological function and energy metabolism in the central nervous system, J. Neurochem., 29, 13, 10.1111/j.1471-4159.1977.tb03919.x Tanda, 1997, Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism, Science, 276, 2048, 10.1126/science.276.5321.2048 Tsou, 1996, Suppression of noxious stimulus-evoked expression of Fos protein-like immunoreactivity in rat spinal cord by a selective cannabinoid agonist, Neuroscience, 70, 791, 10.1016/S0306-4522(96)83015-6 Tsou, 1998, Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system, Neuroscience, 83, 393, 10.1016/S0306-4522(97)00436-3 Volkow, 1991, Cerebellar metabolic activation by delta-9-tetrahydro-cannabinol in human brain: a study with positron emission tomography and 18F-2-fluoro-2-deoxyglucose, Psychiatry Res., 40, 69, 10.1016/0925-4927(91)90030-T Wagner, 2001, Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors, Eur. J. Pharmacol., 423, 203, 10.1016/S0014-2999(01)01112-8 Whitlow, 2002, Metabolic mapping of the time-dependent effects of delta 9-tetrahydrocannabinol administration in the rat, Psychopharmacology (Berl.), 161, 129, 10.1007/s00213-002-1001-x